Semapimod cytokine

Current Opinion in Investigational Drugs

Volumn 4, Issue 11, 2003, Pages 1363-1368

  Sitaraman, Shanthi V ^a   Hoteit, Marouf ^a   Gewirtz, Andrew T ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AXD 455; CREATININE; GAMMA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 1BETA; INTERLEUKIN 2; LIVER ENZYME; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SEMAPIMOD; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; CROHN DISEASE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TOLERABILITY; HUMAN; INFLAMMATION; LIVER TOXICITY; NEPHROTOXICITY; NONHUMAN; PANCREATITIS; PHLEBITIS; PSORIASIS; REVIEW; SIDE EFFECT; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS, PHASE I; CLINICAL TRIALS, PHASE II; CYTOKINES; HUMANS; HYDRAZONES; INFLAMMATION; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME;

EID: 0345832384     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (31)

1. 185984 An inhibitor of macrophage arginine transport and nitric oxide production (semapimod) prevents acute inflammation and endotoxin lethality. Bianchi M, Ulrich P, Bloom O, Meistrell M, Zimmerman GA, Schmidtmayerova H, Bukrinsky M, Donnelley T, Bucala R, Sherry B et al. Mol Med 1995 1 3 254-266
2. 288421 Cytokine Networks begins clinical trial of compound to inhibit toxic side effects of IL-2 cancer therapy. Cytokine Networks Inc Press Release 1998 May 28
3. 312904 The tetravalent guanylhydrazone semapimod blocks the toxic effects of interleukin-2 without diminishing antitumor efficacy. Kemeny MM, Botchkina GI, Ochani M, Bianchi M, Urmacher C, Tracey KJ Proc Natl Acad Sci USA 1998 95 8 4561-4566
4. 312907 Macrophage pacification reduces rodent pancreatitis-induced hepatocellular injury through down-regulation of hepatic tumor necrosis factor α and interleukin-1β. Yang J, Denham W, Carter G, Tracey KJ, Norman J Hepatology 1998 28 5 1282-1288
5. 312912 The physiologic consequences of macrophage pacification during severe acute pancreatitis. Yang J, Denham W, Tracey KJ, Wang H, Kramer AA, Salhab KF, Norman J Shock 1998 10 3 169-175
6. 312913 Semapimod prolongs survival and reduces myocyte loss, apoptosis, and inflammation during rat allograft rejection. Yang X, Szablocks M, Minanov O, Ma N, Sciacca RR, Bianchi M, Tracey KJ, Michler RE, Cannon PJ J Cardiovascular Pharmacol 1998 32 1 146-155
7. 312914 Targeted suppression of cytokine production in monocytes but not in T lymphocytes by a tetravalent guanylhydrazone (semapimod). Bjork L, Tracey KJ, Ulrich P, Bianchi M, Cohen PS, Akerlund K, Fehniger TE, Andersson U, Andersson J J Infect Dis 1997 176 5 1303-1312
8. 312918 Semapimod inhibits monocyte/macrophage tumor necrosis factor by suppression of translation efficiency. Cohen PS, Nakshatri H, Dennis J, Caragine T, Bianchi M, Cerami A, Tracey KJ Proc Natl Acad Sci USA 1996 93 9 3967-3971
9. 312919 Suppression of proinflammatory cytokines in monocytes by a tetravalent guanylhydrazone. Bianchi M, Bloom O, Raabe T, Cohen PS, Chesney J, Sherry B, Schmidtmayerova H, Calandra T, Zhang X, Bukrinsky M, Ulrich P et al. J Exp Med 1996 183 3 927-936
10. 326936 Inhibition of multiple inflammatory mediators during severe acute pancreatitis: The beneficial effects of macrophage pacification. Murphy C, Yang J, Denham W, Norman J Gastroenterology 1999 Abs 1831
11. 330557 Potential new therapies for the treatment of acute pancreatitis. Denham W, Norman J Expert Opin Investig Drugs 1999 8 7 973-982
12. 366387 Pancreatic elastase activates pulmonary NF-κB and IκB mimicking pancreatitis-associated ARDS. Jaffray C, Yang J, Norman J Gastroenterology 2000 118 4 Suppl 2 Abs 943
13. 383554 Cytokine PharmaSciences grants license to Axxima Pharmaceuticals. Cytokine PharmaSciences Inc Press Release 2000 September 26
14. 386733 Cytokine PharmaSciences forms joint venture with Elan to develop cytokine inhibitor. Cytokine Networks Inc Press Release 2000 October 23
15. 388260 Efferent vagus nerve activity attenuates cytokine-mediated inflammation. Borovikova LV, Ivanova S, Watkins LR, Tracey KJ Abstr Soc Neurosci 2000 26 1 Abs 442.17
16. 390226 Exaggerated pain from sciatic inflammatory neuritis (SIN) is mediated by spinal cord glial activation. Chacur M, Armstrong CB, Watkins LR, Milligan ED, Gazada L, Myers RR, Martin D, Tracey KJ, Maier SF Abstr Soc Neurosci 2000 26 2 Abs 733.3
17. 390961 Inhibition of cytokine release by intraperitoneal semapimod blocks peri-spinal gp120-induced enhanced pain. Milligan ED, O'Connor KA, Borovikova L, Tracey KJ, Martin D, Maier SF, Watkins LR Abstr Soc Neurosci 2000 26 2 Abs 733.2
18. 409510 A new MAP-kinase inhibitor semapimod, is a safe and effective in the treatment of moderate to severe Crohn's disease. Hommes DW, van den Blink B, Van de Heisteeg B, Plasse T, de Ley M, Bartelsman JFW, van Deventer SJH, MacPherson B Gastroenterology 2001 120 5 Suppl 1 Abs 2305
19. 409806 Digestive Disease week 2001 (Part II) - Overnight Report, Atlanta, GA, USA. Hilton J IDDB Meeting Report 2001 May 20-23
20. 426089 Axxima's novel mechanism of action drug AXD-455 enters clinical trials to fight HIV. Axxima Pharmaceuticals AG Company World Wide Web Site 2001 October 18
21. 426715 Axxima's novel mechanism of action drug AXD-455 enters clinical trials to fight HIV. Axxima Pharmaceuticals AG Press Release 2001 August 09
22. 432894 Cytokine PharmaSciences Inc: About Cytokine PharmaSciences, Products and Partnering. Cytokine PharmaSciences Inc Company World Wide Web Site 2001 December 10
23. 449347 A phase I study of semapimod, an inhibitor of cytokine release, in combination with high-dose interleukin-2 in patients with renal cancer and melanoma. Atkins MB, Redman B, Mier J, Gollob J, Weber J, Sosman J, MacPherson BL, Plasse T Clin Cancer Res 2001 7 3 486-492
24. 464411 Synergism in TNF inhibition and survival to endotoxic shock in rats given microencapsulated semapimod and antisense oligomers to NF-κB. Oettinger CW, D'Souza MJ ICAAC 2002 42 Abs B956
25. 465087 Drug development pipeline: AXD-455; HCV & HBV projects. Axxima Pharmaceuticals AG Company Communication 2002 September 26
26. 478285 Pharmacological stimulation of the cholinergic antiinflammatory pathway. Bernik TR, Friedman SG, Ochani M, DiRaimo R, Ulloa L, Yang H, Sudan S, Czura CJ, Ivanova SM, Tracey KJ J Exp Med 2002 195 6 781-788
27. 484268 Cytokine PharmaSciences Inc: Products. Cytokine PharmaSciences Inc Company World Wide Web Site 2003 April 01
28. 504220 Elan Corp plc: 2002 Annual report. Elan Corp Plc Annual Report 2003 September 05
29. 507339 Tracing the cholinergic anti-inflammatory pathway. Ulloa L, Ochani M, Pavlov V, Liao H, Tracey KJ FASEB J 2003 17 4-5 Abs 866.27
30. 507349 Spinal glia and proinflammatory cytokines mediate mirro-image neuropathic pain in rats. Milligan ED, Twining C, Chacur M, Biedenkapp J, O'Connor K, Poole S, Tracey K, Martin D, Maier SF, Watkins LR J Neurosci 2003 23 3 1026-1040
31. 510355 Bridging discovery and innovation. Cytokine PharmaSciences Inc Company World Wide Web Site 2003 October 24